ClinicalTrials.gg
Active, not recruitingNCT06211036DeLLphi-305Updated Nov 6, 2026

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

A Phase 3 interventional study of Tarlatamab and Durvalumab in Extensive-Stage Small-Cell Lung Cancer and Small-Cell Lung Cancer, sponsored by Amgen. Active, not recruiting at 219 sites in 29 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Updated Nov 6, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
563
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing AMG 757 in Small Cell Lung Carcinoma — 9 open to participants now, 17 under way, 6 of them phase 3. AMG 757 · Small Cell Lung Carcinoma.

Enrollment
Largest of 18
563 · median 221
Started
2024
with 2 others
Phase 3
6 of 18
2 open now
Primary completion
2030-04
later than 12 of 16 live
Registered
5th of 18
by date
Lead sponsor
11 of 18
Amgen

Among the 18 studies testing AMG 757 in Small Cell Lung Carcinoma, this one has the largest enrollment, is one of 3 that started in 2024, is one of 6 in phase 3, reaches primary completion later than 12 of the 16 other live ones, and was the 5th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

9 of the 18 studies testing AMG 757 in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About AMG 757

AMG 757: first FDA approval 2024 (IMDELLTRA), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing AMG 757 in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).

03

Conditions studied

  • Extensive-Stage Small-Cell Lung Cancer
  • Small-Cell Lung Cancer

Keywords

  • Extensive-Stage Small-Cell Lung Cancer
  • ES-SCLC
  • Platinum
  • Etoposide
  • Durvalumab
  • Tarlatamab
  • AMG 757
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has provided prior to initiation of any study specific activities/procedures.
  • Age >= 18 years (or >= legal adult age within the country if it is older than 18 years).
  • Completed 3-4 cycles of platinum-etoposide chemotherapy with concurrent durvalumab as treatment of extensive-stage (ES)-SCLC prior to enrollment, without disease progression (ongoing response or stable disease) per Version 1.1 (RECIST 1.1).
  • (ECOG) performance status (PS) of 0 to 1.
  • Minimum > 12 weeks.
  • Toxicities attributed to prior anti-cancer therapy resolved to grade ≤ 1, unless otherwise specified, excluding alopecia or fatigue.
  • Adequate organ function.
  • or cytologically documented extensive-stage disease (American Joint Committee on Cancer, 2017, IV small-cell lung cancer (SCLC) [T any, N any, M1 a/b/c]), or T3 to T4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan. Participants with prior limited-stage (LS)-SCLC are allowed if the interval is > 6 months since the end of previous therapy and progression, in discussion with the medical monitor.

Exclusion criteria

Exclusion

  • Symptomatic central nervous system (CNS) , or . Participants with treated are eligible as per protocol.
  • Prior history of severe or life-threatening events from any immune-mediated therapy.
  • History of other within the past 2 years, with some exceptions as per protocol.
  • Active or prior documented or inflammatory disorders as per protocol.
  • Myocardial infarction and/or symptomatic congestive heart failure ( > class II) within 6 months of first dose of study treatment.
  • History of arterial thrombosis (e.g., stroke or ) within 6 months of first dose of study treatment.
  • Evidence of interstitial lung disease (ILD) or active, non-infectious pneumonitis.
  • History of solid organ transplant.
  • Major surgical procedures within 28 days of first dose of study treatment.
  • Known (HIV) infection (participants with HIV infection on antiviral therapy and undetectable viral load are permitted with a requirement for regular monitoring for reactivation for the duration of treatment on study), infection (participants with hepatitis C that achieve a sustained virologic response after antiviral therapy are allowed), or infection (participants with hepatitis B surface antigen [HBsAg] or core antibody that achieve sustained virologic response with antiviral therapy are permitted with a requirement for regular monitoring for reactivation for the duration of treatment on the study).
  • Receiving systemic therapy or any other form of therapy within 14 days prior to first dose of study treatment.
  • History of allergic reactions or acute reaction to antibody therapies, platinum chemotherapy, or etoposide.
  • Participant with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days prior to the first dose of study treatment.
  • Participant has known active infection requiring parenteral antibiotic treatment. Upon completion of parenteral antibiotics and resolution of symptoms, the participant may be considered eligible for the study from an infection standpoint.
  • Treatment with live virus, including , within 4 weeks prior to the first dose of study treatment. Inactive vaccines (e.g., non-live or non-replicating agent) and live viral non-replicating vaccines (e.g., Jynneos for Monkeypox infection) within 30 days prior to first dose of study treatment.
  • Prior therapy with any selective inhibitor of the delta-like ligand 3 (DLL3) pathway.
  • Receiving another anti-cancer therapy. hormonal therapy for resected breast cancer is permitted.
  • Treatment in an alternative trial within 28 days prior to enrollment.
  • Has received or is planning to receive consolidative chest radiation for extensive stage disease.
  • Female participants of unwilling to use protocol specified method of during treatment as per protocol.
  • Female participants who are breastfeeding or who plan to breastfeed while on study as per protocol.
  • Female participants planning to become pregnant or donate eggs while on study as per protocol.
  • Female participants of childbearing potential with a positive pregnancy test assessed at screening by a highly sensitive serum pregnancy test.
  • Male participants with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment as per protocol.
  • Male participants with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment as per protocol.
  • Male participants unwilling to abstain from donating sperm during treatment as per protocol.
  • Participant has known sensitivity to any of the products or components to be administered during dosing.
  • Participant has known sensitivity to any of the products or components to be administered during dosing.
  • History or evidence of any other disorder, condition or disease that, in the opinion of the investigator or physician if consulted, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
  • Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (eg, Clinical Outcome Assessments) to the best of the participant and investigator's knowledge. Participants who are unable to complete clinical outcome assessments are eligible.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
563 participants (actual)

Study arms

  • Experimental
    Tarlatamab in Combination With Durvalumab

    Participants will receive tarlatamab once every 2 weeks (Q2W) and durvalumab once every 4 weeks (Q4W).

    Drug: Tarlatamab · Drug: Durvalumab

  • Active comparator
    Durvalumab Alone

    Participants will receive durvalumab Q4W alone.

    Drug: Durvalumab

Interventions

06

What researchers measure

Primary outcomes

  1. OS

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Progression Free Survival (PFS)

    Time frame: Up to approximately 3 years

  2. Overall Response (OR)

    Time frame: Up to approximately 3 years

  3. Disease Control (DC) Rate

    Time frame: Up to approximately 3 years

  4. Duration of Response (DoR)

    Time frame: Up to approximately 3 years

  5. PFS at 6 Months

    Time frame: 6 months

  6. PFS at 1 Year

    Time frame: 1 year

  7. PFS at 2 Years

    Time frame: 2 years

  8. OS at 6 Months

    Time frame: 6 months

  9. OS at 1 Year

    Time frame: 1 year

  10. OS at 2 Years

    Time frame: 2 years

  11. OS at 3 Years

    Time frame: 3 years

  12. Time to Progression (TTP)

    Time frame: Up to approximately 3 years

  13. Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 9 months

  14. Number of Participants with TEAEs Grade 3 or Above per Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

    Time frame: Up to approximately 3 years

  15. Number of Participants with Serious TEAEs

    Time frame: Up to approximately 3 years

  16. Number of Participants with TEAEs Leading to Discontinuation of Treatment

    Time frame: Up to approximately 3 years

  17. Number of Participants with Fatal TEAEs

    Time frame: Up to approximately 3 years

  18. Number of Participants with Treatment-related Adverse Events (AEs)

    Time frame: Up to approximately 9 months

  19. Number of Participants with Adverse Events of Interest (EOI)

    Time frame: Up to approximately 9 months

  20. Serum Concentrations of Tarlatamab

    Time frame: Day 1 up to approximately 6 months

  21. Number of Participants with Antitarlatamab Antibody Formation

    Time frame: Up to approximately 9 months

  22. Time to First Deterioration (TTD) for Physical Function as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30 (EORTC-QLQ-C30)

    Time frame: Baseline to Week 13 and Week 25

  23. Change in Disease Symptoms of Cough as Measured Using EORTC-QLQ LC13

    Time frame: Baseline to Week 13 and Week 25

  24. Change in Disease Symptoms of Chest Pain as Measured Using EORTC-QLQ LC13

    Time frame: Baseline to Week 13 and Week 25

  25. Change in Disease Symptoms of Dyspnea as Measured Using EORTC-QLQ LC13

    Time frame: Baseline to Week 13 and Week 25

  26. TTD for Global Health Status as Measured by EORTC-QLQ-C30

    Time frame: Baseline to Week 13 and Week 25

  27. TTD for Quality of Life as Measured by EORTC-QLQ-C30

    Time frame: Baseline to Week 13 and Week 25

07

Study locations

219 sites

Showing the first 100 of 219 sites across 29 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Perol M, Yoshida T, Ahn MJ, Gay CM, Schuler M, Liu H, Sezer A, Bilici A, Korantzis I, Lim SM, Otsubo K, Juan-Vidal O, Chen Y, Schvartsman G, Wang H, Dingemans AC, Clarke JM, Desai A, Marigil M, Chen Y, Abidi B, Wang J, Sands J; DeLLphi-305 Investigators. Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2026 Oct 24. doi: 10.1056/NEJMoa2609482. Online ahead of print. PubMed 42929702 ↗
  • Paulson KG, Lau SCM, Ahn MJ, Moskovitz M, Pogorzelski M, Hafliger S, Parkes A, Zhang Y, Hamidi A, Thompson CG, Wermke M. Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study. Lancet Oncol. 2025 Oct;26(10):1300-1311. doi: 10.1016/S1470-2045(25)00480-2. Epub 2025 Sep 8. PubMed 40934933 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Apr 2030, 69 months after the start.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's planned 69 months is above that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Jul 2027 → Apr 2030 and completion Sep 2028 → Apr 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2024
First posted
Jan 18, 2024
StartActual
Jun 5, 2024
Primary completionEst.
Apr 2, 2030was Jul 2027
CompletionEst.
Apr 2, 2030was Sep 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 5, 2027→Apr 2, 2030
Nov 6, 2026
Study completion
Sep 30, 2028→Apr 2, 2030
Nov 6, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42929702 ↗
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42929702 ↗
    Primary completion Jul 5, 2027→Apr 2, 2030
    Study completion Sep 30, 2028→Apr 2, 2030
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06211036
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jan 18, 2024
Start date
Jun 5, 2024
Primary completion
Apr 2, 2030 (estimated)
Completion
Apr 2, 2030 (estimated)
Last update
Nov 6, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AMG 757

Start the discussion